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Abstract 
Osteoporosis is associated with an increased risk for atypical fractures (Dunphy, Winland-
Brown, Porter & Thomas, 2015). It is a disease affecting eight-million women and two-million 
men in the United States of America. This disease is largely associated with advanced age, 
female gender and other comorbidities, and proper treatment is essential. Multiple treatment 
modalities are available, both pharmacologic and non-pharmacologic (Lindsay & Cosman, 
2018). Recommendations for prevention of osteoporotic fracture are prevalent, but 
recommendations regarding pharmacologic treatment in the post-operative period is lacking. One 
pharmacologic treatment, Bisphosphonate (BP) therapy, remains controversial; as evidence 
regarding safety for patients in the post-operative recovery period is minimal (Cho et al., 2015). 
The following is a case analysis with a thorough literature review highlighting the risks and 
benefits of administering BP therapy to osteoporotic patients in the post-operative period. 
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Risks and Benefits of Administering Bisphosphonates with a  
Diagnosis of Atypical Osteoporotic Fracture 
Background 
Osteoporosis 
 Osteoporosis is a reduction in bone strength that leads to deterioration of human skeletal 
framework and is associated with an increased risk for fractures (Dunphy, Winland-Brown, 
Porter & Thomas, 2015). A clinical diagnosis of osteoporosis is identified by a bone mineral 
density (BMD) of 2.5 standard deviations (SD) below the mean for healthy adults; the BMD is 
measured radiographically via the dual energy x-ray absorptiometry (DXA) scan in the lumbar 
spine, total hip or femoral neck, and is also known as the T-score (Lindsay & Cosman, 2018). 
 The development of osteoporosis is largely based on nonmodifiable and potentially 
modifiable risk factors. Nonmodifiable risk factors include female gender, advanced age, 
Caucasian race, genetics, comorbid dementia and personal history of fracture as an adult. 
Potentially modifiable risk factors include tobacco use, a history of glucocorticoid use, estrogen 
deficiency, inadequate nutrition hindering calcium and vitamin D intake, alcoholism, falls and 
inadequate physical activity (Lindsay & Cosman, 2018). 
 With osteoporosis comes an increased risk for atypical osteoporotic fractures, which 
often require surgical intervention for repair. The practitioner’s goal for treatment of patients 
with osteoporosis is to prevent and manage acute fractures, while treating the underlying disease 
process. The first step in treating osteoporosis is to reduce the impact of modifiable risk factors 
such as those listed previously in this paper. Lifestyle changes regarding nutrition intake and 
physical activity are typically involved in the plan of care. Pharmacologic interventions are also 
utilized; these include Vitamin D and Calcium supplementation, Selective Estrogen Receptor 
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Modulators (SERMs), hormone replacement therapy (HRT) and bisphosphonates (BP). These 
medications are Food and Drug Administration (FDA) approved for the prevention and treatment 
of osteoporosis (Lindsay & Cosman, 2018). 
Bone Remodeling 
 This paper is largely focused on the effects of BP activity on bone recovery. 
Understanding the mechanism of action of BP therapy requires knowing how the human body 
performs bone-turnover or remodeling following a fracture. Bone remodeling involves the 
combined activity of cells called osteoclasts and osteoblasts. Osteoclasts are multinucleated cells 
that remove damaged bone and resorb calcified bone matrix during bone remodeling. Osteoblasts 
are cells that secreted organic components into the bony matrix to synthesize the formation of 
bone (Mescher, 2018). Effective bone remodeling requires continuous resorption of bone tissue 
equal to the amount of new bone being laid down at a given site. Following the fracture of a 
bone, blood vessels form a clot around the site which is eventually replaced by a hard callus 
created by osteoblasts. Eventually the callus is invaded by the vasculature, allowing osteoclasts 
to enter the area to resorb the hard callus into woven bone. A secondary remodeling phase 
follows, which includes more resorption by osteoclasts, remodeling of the original fractured bone 
below the callus, and formation of laminar bone via osteoblasts. (Lindsay & Cosman, 2018; 
Kates & Ackert-Bicknell, 2016).  
 Bisphosphonates work to combat osteoporosis by directly impairing osteoclast resorption 
function. They also work to reduce the presence of osteoclasts in the human body by apoptosis 
(Lindsay & Cosman, 2018). Use of BP therapy is controversial because of the potential 
theoretical risk of suppression of bone turnover and impairment of bone remodeling (Koh, 
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Guerado, & Giannoudis, 2017). In theory, the use of BP could interfere with fracture healing in 
patients with osteoporosis due to decrease osteoclast function (Cho et al., 2015). 
Purpose 
The purpose of this paper is to identify what risks or benefits, if any, there are in 
administering BP therapy to patients with a clinical diagnosis of atypical osteoporotic fracture 
requiring surgical intervention. Accompanying a thorough literature review is a case study 
involving a seventy-two-year-old woman, with a recent diagnosis of atypical femoral fracture, 
who presents to the clinic following surgical repair.  
Case Report 
 A seventy-two-year-old female presents to the outpatient clinic for a follow-up 
evaluation. She was recently discharged from the hospital after a three-day-stay after an open 
reduction and internal fixation (ORIF) of her right hip, originating from an at-home fall. Her past 
medical history includes Chronic Obstructive Pulmonary Disorder (COPD), Anemia, 
Hypertension, Hypercholesterolemia and tobacco use, one pack per day for forty-five years. Her 
current medications include Fluticasone-propionate and salmeterol, Metoprolol, Quetiapine and 
Iron sulfate, twice a day, and Losartan, Paroxetine, Lipitor and a multivitamin, daily. Most 
recently she completed a Prednisone taper following an acute COPD exacerbation. A thorough 
social history reveals she is widowed, lives alone, follows a dairy-free diet, and performs daily 
home exercises she learned at physical therapy, of which she completed a week ago. 
Review of her symptoms finds she is “feeling more tired than usual”, is experiencing a 
new-onset poor appetite, and occasional pain in her right hip, rated a 3/10, occurring before bed, 
described as aching, exacerbated by overuse and relieved by acetaminophen and rest. Physical 
examination reveals a normal exam, with full range of motion, good strength, balance and 
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reflexes in bilateral lower extremities. Visualization of her surgical incision shows a well-
healing, approximated incision, negative for swelling, drainage, erythema or pain with palpation.  
Assessment of the patient’s risks for fracture including age, post-menopausal state, 
chronic tobacco use, dairy-free diet and history of glucocorticoid use prompted further 
evaluation to determine the etiology of her right hip fracture.  A dual energy x-ray 
absorptiometry (DXA) scan was ordered to assess her bone mineral density and the results of the 
scan are were a T-score of -2.6, which is diagnostic of osteoporosis. Her agreed-upon treatment 
plan included supplemental administration of Calcium, 1,200 mg, and vitamin D, 800 
international units daily and incorporating a daily oral bisphosphonate, while continuing at-home 
exercises and joining her local Silver Sneakers program. Follow-up evaluation of her physiologic 
response to her treatment included a plan to reassess her bone mineral density with a repeat DXA 
scan in two years.   
Literature review 
In conducting a literature review, articles were reviewed using the Cumulative Index of 
Nursing and Allied Health Literature (CINAHL), MEDLINE Complete, Pubmed and Pubmed 
Central (PMC) databases. Limitations applied to the search included available articles published 
within five years (2014-2019), pertaining to the adult population, of whom experienced an 
atypical osteoporotic long-bone fracture, was treated with surgical repair and received 
bisphosphonates in the pre- or post-operative periods. These criteria revealed a narrow amount of 
information, so the search was expanded to include surgical repair of osteoporotic joints, which 
yielded outcomes of bisphosphonate use with osteoporotic knee and hip arthroplasties; a total of 
eleven articles were utilized in this review. 
Summary of Findings 
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 Utilizing the Oxford Centre for Evidence-Based Medicine (CEBM) Levels of Evidence 
(2011), eleven articles were evaluated, and the findings summarized. The levels are evidence are 
rated from level 1 to 5: level 1 evidence is systematic reviews of randomized control trials 
(RCT), individual RCT and meta-analyses. Level 2 evidence is from systematic reviews of 
cohort studies and individual cohort studies, level 3 evidence stems from review of case-control 
studies and individual case-control studies, level 4 evidence includes case series, case control 
and poor-quality cohorts, and finally, level 5 evidence includes expert opinions, experimental 
research and animal studies. The level of evidence is most credible with a level 1 rating (Howick 
et al., 2011).   
 Level 1 evidence from a meta-analysis of 2,500 patients with differing osteoporotic 
fractures found that anti-osteoporotic medications such as BPs, which possess antiresorptive 
activity, showed no clinically significant delay in fracture healing and are safe to be given in the 
pre- and post-operative period to reduce the incidence of future fractures (Bartl, Stengel, Gulke, 
& Gebhard, 2016). Li, Cai & Zhang (2015) formed a meta-analysis evaluating for a delay in 
healing based on clinical and radiologic findings and bone-turnover markers. This is another 
example of level 1 evidence that patients treated with BP therapy less than three months post-
operatively had no significant differences in healing time when compared to non-BP-users. 
Recommendation was made for BP therapy to be started immediately following surgical repair 
as there was also level 1 evidence this would prevent subsequent fractures. (Li et al., 2015). 
 Ng, Yue, Joseph & Richardson (2014) found level 2 evidence found stating that initiating 
BP therapy at different times following an atypical osteoporotic fracture showed no difference in 
healing time. The benefit of BP therapy for prevention of future fractures in such patients 
outweighs risk of non-union (Ng, Yue, Joseph & Richardson, 2014). Kates & Ackert-Bicknell 
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(2016) also found level 2 evidence of no delay in bone-union with initiation of BPs immediately 
after diagnosis of an atypical osteoporotic long-bone fracture. Patients already on long-term BP 
therapy had a delay in bone-union 26% of the time, however, insufficient data prevented the 
analysis from being fully understood (Kates & Ackert-Bicknell, 2016). Xue Li, Chen, Yan & Pan 
(2014) evaluated the treatment of patients with BPs during bone healing and level 1 evidence 
showed there is no association with BP use, delay in direct bone healing or fracture nonunion. 
Also, delaying the administration of BPs following a confirmed atypical osteoporotic fracture 
had no effect on bone healing. Finally, this meta-analysis confirmed recommendations that 
treatment BPs should be done after the first osteoporotic fracture to increase bone mineral 
density and reduce the risk of future fractures (Xue et al., 2014). 
 A case-control study compared outcomes of bisphosphonate naïve patients who were 
administered BPs any time during a twenty-four-month post-operative period with BP naïve 
patients who were non-users of these drugs. The rate of new clinical fracture was found to be 
increased in BP users during the first six months of treatment, the difference eventually 
decreasing over time, and by month eighteen, the rate of fracture was similar for both cohorts. 
Level 3 evidence was used to support administering BPs as beneficial to the patient upon clinical 
diagnosis of an atypical osteoporotic fracture (Bergman, Nordström & Nordström 2018). 
Alternatively, Prieto-Alhambra et al. (2014) found level 3 evidence suggesting osteoporotic 
patients who received total knee or hip arthroplasties and became BP users for at least six months 
in the post-operative period had a fifty-nine percent reduced risk for surgical revision (Prieto-
Alhambra et al., 2014). 
 Level 3 evidence states there is no statistical evidence to support delayed or non-healing 
bone following repair of an osteoporotic fracture. Recommendation was made for patients who 
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have taken BPs for five years or more, that they may have an increased risk for a decrease in 
bone formation and remodeling, therefore requiring surgery to be performed by experienced 
surgeons. Further, a suggestion was made for patients to have a ‘drug holiday’ after five years of 
BP therapy to prevent such complications (Phillips, Harrison, Akrawi & Sidhom, 2017). These 
findings are somewhat contradictory to Koh, Guerado & Giannoudis (2017) who found level 2 
evidence of no significant different in length of healing time in comparing patients taking BPs 
for less than five years versus patients taking BPs greater than five years. It also suggests there is 
no clinically significant risk of revisional surgery in either of these patient groups (Koh, Guerado 
& Giannoudis, 2017). 
 In comparing patients with osteoporotic intertrochanteric fractures who received BP 
therapy at either one week, one month or three months following surgical repair, the time of bone 
union, as evidenced by radiographic callus formation, there was no significant difference in bone 
union. This confirmed level 2 evidence that delaying initiation of BPs in the post-operative 
period does not affect the length of healing time. Subsequently, early administration of BPs was 
found to prevent future osteoporotic fractures (Cho et al., 2015).  
Finally, a study comparing osteoporotic patients with atypical fractures of the proximal 
humerus were evaluated for length of time for radiographic bone-union when receiving BP 
therapy starting at either two weeks or three months into the post-operative period. Level 2 
evidence found that delaying BP treatment does not significantly affect healing outcomes in 
these patients (Seo, Yoo, Ryu & Yu, 2016). 
Recommendations for Practice  
• Use of bisphosphonates in the post-operative period does not increase healing time or 
prevent bone-union in surgically repaired atypical osteoporotic fractures.  
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• Delaying administration of bisphosphonates is not beneficial in patients with a confirmed 
clinical diagnosis of atypical osteoporotic fracture, who are having surgical repair.  
• Administering bisphosphonates to patients with a confirmed clinical diagnosis of atypical 
osteoporotic fracture is beneficial in preventing future fractures.  
Conclusion 
 Osteoporosis remains a major health concern among post-menopausal women and at this 
time, BP therapy is the most widely used treatment for it (Li et al., 2015). With thoughtful 
consideration of information found in the thorough literature review, recommendations for 
practice can be made for administration of BP’s with a concurrent diagnosis of atypical 
osteoporotic fracture as it relates the case presented. Although there was a variety of level one 
evidence regarding the benefit of BP’s immediately upon diagnosis, the risk of impaired bone 
healing is still somewhat unknown. Until stronger research is presented regarding impaired bone 
healing, the benefit of anti-osteoclastic activity associated with BP use outweighs hypothesized 
risk.  
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